AstraZeneca to buy Alexion for $39bn

AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Indian court rejects AstraZeneca’s injunction request

24 November 2020 The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.

Americas

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

18 November 2020 Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.

More on this story

Big Pharma

Indian court rejects AstraZeneca’s injunction request

24 November 2020 The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.

Americas

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

More on this story

Big Pharma

Indian court rejects AstraZeneca’s injunction request

24 November 2020 The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.

Americas

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen